contraindications to glp 1 agonists Clinical Focus on GLP-1 in Type 2 Diabetes Mellitus TrimRX | GLP-1 vs GIP:

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic poly-peptide (GIP, previously known as gastric inhibitory polypeptide) are key incretin

While newly approved pharmacotherapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show efficacy, their clinical utility remains constrained by dose-dependent gastrointestinal complications, underscoring the urgent need for safer alternatives

Tirzepatide & Semaglutide Options Price: Starting at $100/month

A mechanistic guide to this next-generation metabolic peptide.

Certainly, the apparent advantage of tirzepatide, a dual incretin agonist, over GLP-1RA will spark renewed interest in the therapeutic potential of GIP in type 2 diabetes, obesity and related co-morbidities.

Secondary outcomes were each of these events considered separately